Pathophysiology of Pain in Parkinson's Disease: Exploration of the Serotonin System in Positron Emission Tomography (PET [18F]-MPPF)
This project will explore the involvement of the serotonin system in the pathophysiology of PD-related central pain. Thus, the serotonin system will be evaluated in PD patients with and without central pain who will benefit from brain positron emission tomography (PET) allowing in vivo imaging of 5HT1A receptors and multimodal brain MRI including morphometric imaging and functional connectivity (resting state acquisition).
• Patients with PD defined according to United Kingdom Parkinson's Disease Brain Bank (UKPDSBB) criteria
• Patients with stable anti-parkinsonian treatment for at least 4 weeks prior to inclusion
• Patients with a Montreal Cognitive Assessment (MoCA) score \> 25
• Patients with a Hospital Anxiety and Depression Scale (HADS)-D score ≥ 11
• Person affiliated or benefiting from a social security scheme.
• Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research).
• • For patients with pain
• Patients with PD-related central pain defined according to the criteria of Marques et al, 2019
• Patients with chronic central pain (i.e. present for at least 3 months)
• Patients who have average pain over the previous month according to a VAS ≥ 4.
• • For patients without pain
• Patients who do not have pain defined as VAS ≤ 4, meaning that it does not interfere with daily activity.